Boštjan Šeruga

Optimal management of metastatic castration-resistant prostate cancer: Highlights from a European Expert Consensus Panel

John M. Fitzpatrick, Joaquim Bellmunt, Karim Fizazi et al. · European Journal of Cancer · 2014 · 146 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Poor correlation between progression-free and overall survival in modern clinical trials: Are composite endpoints the answer?

Eitan Amir, Boštjan Šeruga, Ryan C. Kwong et al. · European Journal of Cancer · 2011 · 120 citations

Medicine, Biostatistics, Oncology +11

Reporting of Serious Adverse Drug Reactions of Targeted Anticancer Agents in Pivotal Phase III Clinical Trials

Boštjan Šeruga, Lynn Sterling, Lisa Wang et al. · Journal of Clinical Oncology · 2010 · 106 citations · Full text

Pharmacy, Oncology, Pharmacology +14

Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial

Anne M. Horgan, Boštjan Šeruga, Gregory R. Pond et al. · Journal of Geriatric Oncology · 2014 · 78 citations · Full text

Medicine, Oncology, Urology +12

Cancer care workforce in Africa: perspectives from a global survey

Verna Vanderpuye, Nazik Hammad, Yehoda M. Martei et al. · Infectious Agents and Cancer · 2019 · 74 citations · Full text

Medicine, Oncology, Comparative Oncology +13